KNSA - חוב כולל להון Kiniksa Corp

Kiniksa Pharmaceuticals (KNSA) relies on high-tech R&D centers while outsourcing drug manufacturing to third-party contractors. Increased sales of its primary pericarditis treatment have enabled the company to reach break-even and stop depleting its reserves. The price action reflects that the total debt-to-equity ratio is 0.01. This confirms the resilience of a business that monetizes patent protection and the exclusivity of therapies for rare inflammatory pathologies.

This indicator compares total liabilities to net assets, measuring the degree of financial leverage and the business's reliance on external borrowing. For Kiniksa Pharmaceuticals (KNSA), with its high margins in the orphan drug segment, the total debt-to-equity ratio demonstrates how effectively the company balances debt financing and the use of equity to strengthen its market position.